Furthering our understanding of the roles of vimentin and its involvement in disease mechanisms could help develop the IF as a possible biomarker for MASLD and obesity and help identify possible solutions. The gene discussed is VIM; the disease is metabolic dysfunction-associated steatotic liver disease.